MedTrace Logo

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-01-14

No results posted yet for this study

Summary

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Conditions

Interventions

BIOLOGICAL

Nimacimab injection

Nimacimab injection 200 mg

BIOLOGICAL

Nimacimab placebo injection

matching nimacimab placebo injection

COMBINATION_PRODUCT

semaglutide injection

semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg

BIOLOGICAL

Nimacimab 300 mg injection

Nimacimab injection 300 mg

Sponsors & Collaborators

  • Skye Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Development Officer · Skye Bioscience, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2026-11-20
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577090 on ClinicalTrials.gov